Skip to content
value.today

ImmunoGen, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

The newest statements on file are more than two years old.

Your own DCF model

A full discounted-cash-flow model of ImmunoGen, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against its own history

ImmunoGen, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.

Price to sales

75.8×

Now above its median of 15.0×, in the top quarter of its range; range 11.6× to 75.8× over 6 months.

0×19×38×57×76×20202021202220232024Price to sales 76×Median 15×

as of Jan 5, 2024. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Jan 5, 2024.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2022to Dec 31, 2022$109 M$-223 M$-230 M$1 M$-231 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$70 M$-139 M$-169 M$1 M$-171 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$132 M$-44 M$-79 M$1 M$-80 M—SEC annual report (10-K, 20-F)
FY2019to Dec 31, 2019$82 M$-104 M$-88 M$3 M$-91 M—SEC annual report (10-K, 20-F)
FY2018to Dec 31, 2018$53 M$-169 M$-166 M$5 M$-172 M—SEC annual report (10-K, 20-F)
FY2017to Dec 31, 2017$115 M$-96 M$8 M$1 M$7 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.